WuXi Biologics

Price Chart

Risk-Adjusted Performance

Also Listed On

WuXi Biologics (2269) Price Performance

WuXi Biologics (2269) trades on Hong Kong Stock Exchange in HKD. The company is classified in the Healthcare sector under the Biotechnology industry. The stock currently trades at HKD35.72, down 3.93% from the previous close.

Over the past year, 2269 has traded between a low of HKD21.55 and a high of HKD42.18. The stock has gained 65.8% over this period. It is currently 15.3% below its 52-week high.

WuXi Biologics has a market capitalization of $155.17B, with a price-to-earnings ratio of 28.23.

About WuXi Biologics

WuXi Biologics (Cayman) Inc., an investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People's Republic of China, North America, Europe, Singapore, Japan, South Korea, and Australia. It operates through two segments: Biologics and XDC. The company provides a suite of solutions for biologic discovery, from concept to IND, that seamlessly transits to CMC and downstream process development through its contract research, development, and manufacturing organization platforms, including WuXiBody, SDArBodY, T cell engager, Single B Cell Cloning Technology, WuXia, WuXiUP, WuXiUI, and WuXiHigh. It engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, production and sales of medicals, and biologics clinical and manufacturing services; production and sale of medicals; vaccine contract development and manufacturing organization (CDMO) and related business; and engages in investment and material supplier activities. It has a research service agreement with BioNTech SE to discover and investigate monoclonal antibodies for developing next-generation therapeutic product candidates. The company has a strategic collaboration with Sinorda Biomedicine Ltd. for the development and manufacturing of SND006, a novel bispecific antibody, for the potential treatment of inflammatory bowel disease (IBD) and other autoimmune diseases. The company was incorporated in 2014 and is headquartered in Wuxi, China.